BioCentury | May 15, 2020
Product Development

Allogene’s allogeneic CAR T data give first hint of threat to marketed autologous therapies

Phase I data to be presented by Allogene at this year’s ASCO meeting provide the first evidence that allogeneic CAR T therapies could challenge marketed autologous therapies on safety and efficacy. On Thursday, Allogene Therapeutics...
Items per page:
1 - 1 of 1